Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
Basic Information
ID: ALA4680250
Journal: Eur J Med Chem
Title: Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
Authors: Espadinha M,Viejo L,Lopes RMRM,Herrera-Arozamena C,Molins E,Dos Santos DJVA,Gonçalves L,Rodríguez-Franco MI,Ríos CL,Santos MMM
Abstract: N-Methyl-d-aspartate receptors (NMDARs) are crucial for the normal function of the central nervous system (CNS), and fundamental in memory and learning-related processes. The overactivation of these receptors is associated with numerous neurodegenerative and psychiatric disorders. Therefore, NMDAR is considered a relevant therapeutic target for many CNS disorders. Herein, we report the synthesis and pharmacological evaluation of a new scaffold with antagonistic activity for NMDAR. Specifically, a chemical library of eighteen 1-aminoindan-2-ol tetracyclic lactams was synthesized and screened as NMDAR antagonists. The compounds were obtained by chiral pool synthesis using enantiomerically pure 1-aminoindan-2-ols as chiral inductors, and their stereochemistry was proven by X-ray crystallographic analysis of two target compounds. Most compounds reveal NMDAR antagonism, and eleven compounds display IC values in a Ca entry-sensitive fluo-4 assay in the same order of magnitude of memantine, a clinically approved NMDAR antagonist. Docking studies suggest that the novel compounds can act as NMDAR channel blockers since there is a compatible conformation with MK-801 co-crystallized with NMDAR channel. In addition, we show that the tetracyclic 1-aminoindan-2-ol derivatives are brain permeable and non-toxic, and we identify promising hits for further optimization as modulators of the NMDAR function.
CiteXplore: 32248004
DOI: 10.1016/j.ejmech.2020.112242
Patent ID: ┄